Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7090 in Advanced Solid Tumors
NCT02275910Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Oct 2014
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tasurgratinib in solid tumor, sponsored by Eisai Co., Ltd. Primary endpoints: Number of Participants With Dose-limiting Toxicities at 5 weeks and Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events at 2.75 years. Started Oct 2014; status: completed.
02
Drugs
tasurgratinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02275910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275910.